RPL23 and neoplasm: Likewise, the ribosomal proteins S2 and L10a have been explored as tumor antigens for the development of peptide-based cancer immunotherapies [63], and phage display of tumor antigens yielded a panel of antigens specific to squamous cell carcinomas with silencing of ribosomal protein L23 inhibiting proliferation, invasion and cell survival in a mouse disease model [64].